TY - JOUR
AU - Motalleb, Gholamreza
AB - The prevalence of Hepatitis C virus (HCV) is approximately 3% around the world. This virus causes chronic hepatitis, liver cirrhosis and hepatocellular carcinoma. The effectiveness of interferon-α and ribavirin therapy is about 50% and is associated with significant toxicity and cost. Hence, generating new vaccines or drugs is an obligation. However, there is no vaccine available for clinical use. DNA vaccines have some advantages such as producing feasibility and generating intensive cellular and humoral immune responses. Activation and improvement of natural immune defense mechanisms is a necessity for the development of an effective HCV vaccine. This article discusses the current status of therapies for hepatitis C, the promising new therapies and the experimental strategies to develop an HCV vaccine.
TI - Hepatitis C Virus and Vaccine Development
JF - International Journal of Molecular and Cellular Medicine
DA - 0168-10-01
UR - https://www.deepdyve.com/lp/pubmed-central/hepatitis-c-virus-and-vaccine-development-wpSSnWqlwo
SP - 207
EP - 215
VL - 3
IS - 4
DP - DeepDyve
ER -